Back to search resultsSummaryRMgm-787
|
||||||||
*RMgm-787| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 23028336 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 2.34 |
| Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943) |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | D.S. Guttery; R. Tewari |
| Name Group/Department | Centre for Genetics and Genomics, School of Biology, Queens Medical Centre |
| Name Institute | University of Nottingham |
| City | Nottingham |
| Country | UK |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-787 |
| Principal name | ppkl- cl3; ppkl- cl9 |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Normal gametocyte production. Normal gamete formation (exflagellation). Aberrant development of ookinetes. Development of the zygote through stages I–III of ookinete maturity (0–9 h post-fertilisation)was indistinguishable in the ppkl- mutants compared to wild-type. Wild-type controls showed normal progression and maturation to stage IV (at 12 h), with 69% of all macrogamete-derived parasites progressing to stage VI 24 h post-fertilisation. In contrast, the majority of ppkl2 mutants did not progress from stage III to stage IV, but produced a high proportion of abnormal retort forms 24 h post fertilisation (35% of the total population) with only 4% progressing to stage IV–VI. Ookinetes are affected in motility and migration through the midgut wall |
| Oocyst | No oocyst formation. Ookinetes are affected in motility and migration through the midgut wall |
| Sporozoite | No oocyst formation and not sporozoite formation |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation Protein (function) Phenotype Whether the observed defect was sex-specific was examined by performing genetic crosses between ppkl- parasites and lines deficient in either male (map2-) or female (nek4-) gametes. Cross-fertilization with nek4- parasites did not rescue the phenotype, whereas crossing with map2- gametocytes resulted in 26% of all macrogamete-derived parasites progressing to stage VI, revealing that the requirement for the phosphatase is inherited through the female line. |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1329500 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1466100 | ||||||||||||||||||||||||
| Gene product | protein phosphatase containing kelch-like domains | ||||||||||||||||||||||||
| Gene product: Alternative name | PPKL; PPalpha; PfPPα | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | ApaI, XbaI | ||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | The targeting vector for ppkl was constructed using the pBSDHFR plasmid, which contains polylinker sites flanking a Toxoplasma gondii dhfr/ts expression cassette conveying resistance to pyrimethamine. PCR primers P0011P (5'-CCCCGGGCCCCATGTTTTATATTGTGTTTTGGC-3') and P0012P (5'-GGGGAAGCTTCAAACATTCGTTTCTTTAAATGATCC-3') were used to generate a 788 bp fragment of 5' upstream sequence of ppkl from genomic DNA, which was inserted into ApaI and HindIII restriction sites upstream of the dhfr/ts cassette of pBS-DHFR. A 694 bp fragment generated with primers P0013P (5'-CCCCGAATTCCCACCAACCCCACCAAGAAGTCAACCG-3') and P0014P (5'-GGGGTCTAGACCGGCAAATTGATGAAATCGC-3') from the 3' flanking region of ppkl was then inserted downstream of the dhfr/ts cassette using EcoRI and XbaI restriction sites. The linear targeting sequence was released using ApaI/XbaI. | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||